Health Condition 1: I22- Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Conditions
Interventions
None listed
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. North Indian ethnicity 2. CAD patients (stable angina, non ST elevation and ST elevation myocardial infarction) presenting to Cardiology OPD, AIIMS after 30days of PCI up to 180 days 3. Patients receiving dual antiplatelet therapy and on stable dose of clopidogrel upto 150 mg once a day and aspirin upto 150 mg once a day for a minimum period of 30 days 4. Willing to participate in the study
Exclusion criteria
Exclusion criteria: 1. Patients under anti coagulation therapy 2. Use of intensified antiplateletagents other than standard dual antiplatelet therapy 3. h/o Bleeding disorders (Hemophilia, von Willebrand disease), hospitalization related to bleeding 4. Chronic kidney disease (eGFR 5. Any contraindications if elicited to antiplatelet therapy 6. Patients with hemoglobin 7. Patients with platelet count 8. Patients with major surgery within 1 week 9. Patients with regular need of NSAID or prednisone(not taken in past 2 weeks) 10. Females with pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Primary outcome - Association of gene polymorphisms with Prakriti types among the responders and non responders as categorized by Light transmission aggregometry test in north Indian CAD patients receiving dual antiplatelet therapy 2. Co-primary outcome - Association between Prakriti types and the responders and non responders as categorized by Light transmission aggregometry test in north Indian CAD patients receiving dual antiplatelet therapy Timepoint: cross sectional study, data will be recorded/collected once only | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactGautam Sharma
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed